WO2011070039A1 - Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk - Google Patents

Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk Download PDF

Info

Publication number
WO2011070039A1
WO2011070039A1 PCT/EP2010/069111 EP2010069111W WO2011070039A1 WO 2011070039 A1 WO2011070039 A1 WO 2011070039A1 EP 2010069111 W EP2010069111 W EP 2010069111W WO 2011070039 A1 WO2011070039 A1 WO 2011070039A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclopropane
indoline
oxospiro
methyl
chlorophenyl
Prior art date
Application number
PCT/EP2010/069111
Other languages
English (en)
Inventor
Li Chen
Lichun Feng
Yun He
Mengwei Huang
Hongying Yun
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to RU2012126987/04A priority Critical patent/RU2012126987A/ru
Priority to CA2781839A priority patent/CA2781839A1/fr
Priority to JP2012542526A priority patent/JP2013513569A/ja
Priority to ES10790751.1T priority patent/ES2464044T3/es
Priority to CN2010800558075A priority patent/CN102656147A/zh
Priority to EP10790751.1A priority patent/EP2509946B1/fr
Priority to BR112012013847A priority patent/BR112012013847A2/pt
Priority to MX2012006180A priority patent/MX2012006180A/es
Publication of WO2011070039A1 publication Critical patent/WO2011070039A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the invention relates to compounds which are activators of AMP-activated protein kinase (AMPK) and which are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes.
  • AMPK AMP-activated protein kinase
  • the invention relates in particular to a compound of formula (I)
  • R 1 and R 2 are independently selected from hydrogen, alkyl, pyridinyl, phenyl,
  • R 3 is hydrogen, pyridinyl, piperidinyl, carboxypyridinyl, tetrahydropyranyl,
  • piperidinylcarbonyl piperazinylcarbonyl, morpholinylcarbonyl, pyridinylpiperazinylcarbonyl, alkylpiperazinylcarbonyl,
  • R 4 is hydrogen, halogen, carboxy, cyano, trifiuoromethyl or alkylsulfonyl; and n is 0, 1, 2 or 3; or a pharmaceutically acceptable salt or ester thereof.
  • the invention also relates to a process for the manufacture of these novel compounds and medicaments containing them.
  • the compounds of the invention have activation effect on AMP (adenosine monophosphate) -activated protein kinase, which results in lowered blood glucose.
  • AMP adenosine monophosphate
  • the invention thus also concerns the use of such compounds for the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes.
  • Obesity and type 2 diabetes, hypertension, cancer, and cardiovascular disease are diseases that feature serious disturbances in glucose or lipid metabolism that severely affect the health and quality of life of affected individuals. The increasing prevalence of these diseases makes finding new drug targets for treating these syndromes an urgent task.
  • AMP-activated protein kinase acts as a cellular energy sensor and regulator. It is activated by an increase in the cellular AMP:ATP ratio induced by metabolic stress, hormone and nuturient signals. Once activated, AMPK switches on catabolic pathways that generate ATP and switches off ATP-consuming anabolic pathways by acute regulation of the activity of key enzymes in metabolism and chronic regulation of the expression of pivotal transcription factors (Hardie, DG. Nature reviews 8 (2007b), 774- 785; Woods, A et al. Molecular and cellular biology 20 (2000), 6704-6711). The growing evidence of AMPK regulatory effects on glucose and lipid metabolism makes it a potential drug target for treatment of diabetes and metabolic syndrome (Carling, D.
  • Adiponectin stimulates glucose uptake and fatty acid oxidation in vitro by activation of AMPK. Furthermore, it exerts its hypoglycemic effect by decreasing PEPCK and G6Pase expression, whereas the administration of dominant negative al adenovirus reverses the effect in vivo (Yamauchi, T et al. Nature medicine 8 (2002), 1288-1295).
  • AMPK a potential target for treating metabolic syndrome
  • Rosiglitazone is traditionally considered to be a PPARy agonist and exerts its antidiabetic effects through differentiation of adipocytes (Semple, RK et al. The Journal of clinical investigation 116 (2006), 581-589). Recent findings indicate that AMPK may be involved in the antidiabetic effects of rosiglitazone (Brunmair, B et al. The Journal of biological chemistry 277 (2002), 25226-25232; Kadowaki, T et al. The Journal of clinical investigation 116(2006), 1784-1792).
  • metformin an existing antidiabetic agent without a defined mechanism of action
  • recent studies demonstrate that it could activate AMPK in vitro and in vivo by inhibiting complex I (El-Mir, MY et al. The Journal of biological chemistry 275 (2000), 223-228; Owen, MR et al. The Biochemical journal 348 Pt 3 (2000), 607-614; Zhou, G et al. The Journal of clinical investigation 108 (2001), 1167- 1174), and the hypoglycemic effect could be blocked completely by knockout of its upstream kinase LKB1, confirming the key role of AMPK in mediating the antidiabetic effect of metformin (Shaw, RJ et al. Science (New York) N.Y. 310 (2005), 1642-1646).
  • alkyl signifies a saturated, linear- or branched chain alkyl group containing 1 to 8, preferably 1 to 6, more preferably 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, tert- butyl and the like.
  • Preferred "alkyl” groups are methyl, ethyl, isopropyl, tert-butyl.
  • alkoxy signifies a group alkyl-O-, wherein the "alkyl” is as defined above; for example methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, i-butoxy, 2-butoxy, t-butoxy and the like.
  • Preferred alkoxy groups are methoxy and ethoxy and more preferably methoxy.
  • cycloalkyl refers to a saturated carbon ring containing from 3 to 7 carbon atoms, preferably from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Preferred cycloalkyl groups are cyclopropyl and cyclopentyl, cyclopropyl being particularly preferred.
  • halogen or "halo”, alone or in combination, means fluorine, chlorine, bromine or iodine.
  • Halogen is preferably fluorine, chlorine or bromine.
  • halophenyl means phenyl substituted by halogen.
  • carbonyl alone or in combination, refers to the group -C(O)-.
  • amino alone or in combination, refers to primary (-NH 2 -), secondary (-NH-) or tertiary amino (-N-).
  • hydroxy alone or in combination, refers to the group -OH.
  • sulfonyl alone or in combination, refers to the group -S(0) 2 -.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula (I) and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, fiowability and solubility of compounds. It is for example described in Bastin R.J. et al., Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H. et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Preferred are the sodium salts of the compounds of formula (I).
  • “Pharmaceutically acceptable esters” means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as
  • esters methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters.
  • any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.
  • Preferred are the methyl and ethyl esters of the compounds of formula (I).
  • R 1 and R 2 are independently selected from hydrogen, alkyl, pyridinyl, phenyl,
  • R 3 is pyridinyl, carboxypyridinyl, tetrahydropyranyl, dialkylamino, morpholinyl, alkylsulfonylpiperidinyl, alkylpiperazinyl, dialkylaminoalkylpiperazinyl, dialkylaminopyrrolidinyl, carboxyalkyl-lH-imidazolyl, carboxy-lH- imidazolyl or substituted phenyl, wherein substituted phenyl is phenyl substituted with one or two substituents independently selected from alkyl, halogen, carboxy, alkylsulfonyl, alkylaminocarbonyl,
  • alkylsulfonylaminocarbonyl pi eridinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl, pyridinylpiperazinylcarbonyl, alkylpiperazinylcarbonyl, alkylsulfonylpiperazinylcarbonyl, alkylpyrrolidinylalkylaminocarbonyl, alkyl - lH-pyrazolylaminocarbonyl, oxo-oxazolidinyl, oxo-pyrrolidinyl and oxo- imidazolidinyl;
  • R 4 is hydrogen, halogen, cyano, trifluoromethyl or alkylsulfonyl; and n is 0, 1, 2 or 3; or a pharmaceutically acceptable salt or ester thereof.
  • R 1 and R 2 are selected from hydrogen and alkyl and the other one is selected from pyridinyl, halophenyl, alkylsulfonylphenyl, cyanophenyl and trifluoromethylphenyl, or R 1 and R 2 , together with the carbon atom to which they are attached form cycloalkyl or tetrahydropyranyl;
  • R 1 and R 2 are selected from hydrogen and isopropyl and the other one is selected from pyridinyl, fluorophenyl, chlorophenyl, cyanophenyl, methylsulfonylphenyl and trifluoromethylphenyl.
  • R 3 is pyridinyl, carboxypyridinyl, tetrahydropyranyl, dialkylamino, morpholinyl, alkylsulfonylpiperidinyl, alkylpiperazinyl, dialkylaminoalkylpiperazinyl, dialkylaminopyrrolidinyl, carboxyalkyl- lH-imidazolyl, carboxy- lH-imidazolyl or substituted phenyl, wherein substituted phenyl is phenyl substituted with one or two substituents independently selected from alkyl, halogen, carboxy, alkylsulfonyl, alkylaminocarbonyl, alkylsulfonylaminocarbonyl, piperidinylcarbonyl, piperazinylcarbonyl, morpholinylcarbonyl,
  • R 3 is carboxypyridinyl, carboxyalkyl-lH-imidazolyl, carboxyphenyl or phenyl substituted with carboxy and oxo- oxazolidinyl.
  • a compound of formula (I) wherein R 4 is hydrogen, halogen, cyano, trifluoromethyl or alkylsulfonyl is also preferred.
  • a compound of formula (I) wherein R 4 is hydrogen, halogen, carboxy, cyano, trifiuoromethyl or alkylsulfonyl is also preferred.
  • a compound of formula (I) wherein R 4 is hydrogen or halogen.
  • a compound of formula (I) wherein R 4 is hydrogen, halogen or carboxy.
  • R 4 is hydrogen, fluoro or chloro.
  • a compound of formula (I) wherein n is 0 or 1 is preferred. Particularly preferred is a compound of formula (I) selected from
  • R 5 is hydrogen, halogen, oxo-oxazolidinyl, oxo- imidazolidinyl.
  • R 6 and R 7 are independently selected from hydrogen, alkyl, cycloalkyl, alkylsulfonyl, cycloalkylsulfonyl, aminoalkyl and aminocycloalkyl.
  • R 1 , R 2 , R 3 , R 4 and n are as defined above unless otherwise indicated.
  • the compounds of formula la and lb can be prepared according to Scheme 1.
  • Intermediate III is prepared as by the condensation reaction between II and different aldehydes or ketones. Cyclopropanation of III affords the intermediate IV. Alkylation between IV and bromide V affords the ester VI.
  • Ester VII can be obtained by introducing R 5 to the intermediate VI under copper salts catalysts. Hydrolysis of the methyl ester VII gives the corresponding acid la.
  • Amide lb can be prepared by the coupling reaction between the acid la and amine VIII.
  • the condensation reaction between II and different aldehydes is carried out in refiuxing toluene or refiuxing alcohol overnight when using base such as piperidine or pyrrolidine as catalyst.
  • Cyclopropanation of III is carried out in organic solvents such as DMSO at 50°C for several hours by treating trimethylsulfoxoniumiodide with sodium hydride to generate sulfurylide in situation.
  • the reaction can be carried out in a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4-dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone at a temperature between 100°C and 180°C for 15 to 60 minutes under microwave irradiation.
  • the reactions can be carried out at a heated temperature such as 80°C for a longer reaction time without microwave irradiation.
  • introduction of R 5 to the methyl ester VI can be carried out in the presence of a copper source such as copper(I) iodide (Cul), in combination with a ligand such as 2,2'-bipyridine, proline, ⁇ , ⁇ '- dimethyl glycine or ethylene glycol, in the presence of a suitable base such as triethylamine, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium teri-butoxide, potassium teri-butoxide, sodium hydride or l,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
  • a copper source such as copper(I) iodide (Cul)
  • a ligand such as 2,2'-bipyridine, proline, ⁇ , ⁇ '- dimethyl glycine or ethylene glycol
  • a suitable base such as triethylamine, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxid
  • the reaction can be carried out in a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4- dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrolidinone at a temperature between 100°C and 180°C for 15 to 60 minutes under microwave irradiation.
  • a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4- dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrolidinone
  • a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4- dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrolidin
  • Hydrolysis of the methyl esters VII can be carried out in the presence of an aqueous inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide in a solvent such as methanol, 1,4-dioxane or tetrahydrofuran at room temperature for several hours to give the stereoisomers of la.
  • an aqueous inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide
  • a solvent such as methanol, 1,4-dioxane or tetrahydrofuran
  • Conversion of the acids la to the corresponding amides lb with suitable amines VIII can be easily accomplished using well known methods.
  • the reaction is typically carried out in the presence of a coupling reagent such as dicyclohexyl carbodiimide (DCC), benzotriazol-l-yl-oxy-tris-pyrrolidinophosphonium hexafiuorophosphate (PyBop), o-(7- azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafiuorophosphate (HATU), o- (lH-benzotriazol-l-yl)-N,N,W,W-tetramethyluronium hexafiuorophosphate (HBTU) or l-ethyl-3-(3'-dimethylamino)carbodiimide hydrochloride salt (EDCI), in the presence or absence of hydroxy
  • the reaction can be carried out in a solvent such as dichloromethane or ⁇ , ⁇ -dimethylformamide at room temperature for several hours (Montalbetti, C. A. G. N. et al., Tetrahedron 61 (2005) 10827).
  • a solvent such as dichloromethane or ⁇ , ⁇ -dimethylformamide
  • the compounds of formula Ic and Id can be prepared according to Scheme 2.
  • the diazo compound X can be obtained by treating the isatin IX with -toluenesulfonyl hydrazide under basic conditions. Cyclopropanation of alkene XI with diazo compound X by Rh catalyst affords the intermediate XII. Alkylation or arylation of XII with the bromide V afforded the methyl ester XIII. Introduction of R 5 to XIII by using copper salts as catalyst gave intermediate XIV. Hydrolysis of the methyl ester gives the corresponding acids Ic.
  • the hydrolysis can be carried out in the presence of an aqueous inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide in a solvent such as methanol, 1,4-dioxane or tetrahydrofuran at room temperature for several hours. Conversion of the acids Ic to the corresponding amides Id with suitable amines VIII can be easily accomplished using methods well known to someone skilled in the art.
  • the reaction is typically carried out in the presence of a coupling reagent such as dicyclohexyl carbodiimide (DCC), benzotriazol-l-yl-oxy-tris-pyrrolidinophosphonium
  • hexafiuorophosphate PyBop
  • HATU o-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafiuorophosphate
  • HBTU o-(lH-benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafiuorophosphate
  • HBTU l-ethyl-3-(3'-dimethylamino)carbodiimide
  • hydrochloride salt (EDCI), in the presence or absence of hydroxybenzotriazole (HOBt) or ⁇ , ⁇ -dimethylaminopyridine (DMAP), in the presence of a base such as triethylamine or AyV-diisopropyl ethylamine.
  • HOBt hydroxybenzotriazole
  • DMAP ⁇ , ⁇ -dimethylaminopyridine
  • the reaction can be carried out in a solvent such as dichloromethane or ⁇ , ⁇ -dimethylformamide at room temperature for several hours (Montalbetti, C. A. G. N. et al, Tetrahedron 61 (2005) 10827).
  • the compounds of formula Ie can be prepared according to Scheme 3. Alkylation of IV with the alkyl halide XV by using a base such as NaH, K 2 C0 3 or Cs 2 C0 3 in organic solvent such as THF or DMF at room temperature for several hours affords the formula of Ie.
  • the compounds of formula If can be prepared according to Scheme 4. Alkylation of IV with the bromide XVI by using a base such as NaH, K 2 C0 3 or Cs 2 C0 3 in organic solvent such as THF or DMF at room temperature for several hours affords the bromide XVII. If can be obtained by treating XVII with amine VIII under basic condition such as NaH, K2CO3 or Cs 2 C0 3 in organic solvent such as THF or DMF at room temperature.
  • alkylation between IV and the iodide XVIII can be carried out by using bases such as NaH, K2CO3 or CS2CO3 in organic solvents such as THF, DMF at room temperature for several hours.
  • Reductive amination of XX with different amines VIII can be carried out in organic solvents such as DCM, THF by using reducing reagents such as NaBH 4 or NaHB(OAc)3 at room temperature to afford formula Ig.
  • the compounds of formula Ih and Ii can be prepared according to Scheme 6.
  • Ih and Ii can be obtained by alkylation of IV with XXI by using bases such as NaH, K2CO3 or CS2CO3 in organic solvents such as THF or DMF at room temperature for several hours.
  • the compounds of formula Ij and Ik can be prepared according to Scheme 7.
  • the coupling between IV and idoimidazole XXII followed by deprotection in the presence of TFA affords Ij.
  • Subsequent alkylation with XXIII affords formula XXIV.
  • hydrolysis of the methyl esters XXIV provides the corresponding acids Ik.
  • the coupling reaction can be carried out in the presence of a copper source such as copper(I) iodide (Cul), in combination with a ligand such as 2,2'-bipyridine, proline, ⁇ , ⁇ '- dimethyl glycine or ethylene glycol, in the presence of a suitable base such as triethylamine, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium teri-butoxide, potassium teri-butoxide, sodium hydride or l,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
  • a copper source such as copper(I) iodide (Cul)
  • a ligand such as 2,2'-bipyridine, proline, ⁇ , ⁇ '- dimethyl glycine or ethylene glycol
  • a suitable base such as triethylamine, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium teri
  • the reaction can be carried out in a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4- dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone at a temperature between 100°C and 180°C for 15 to 60 minutes under microwave irradiation.
  • a suitable solvent like acetonitrile, dichloromethane, tetrahydrofuran, toluene, benzene, 1,4- dioxane, ⁇ , ⁇ -dimethylformamide, dimethyl sulfoxide or N-methylpyrrolidinone
  • the reactions can be carried out without the use of a microwave at a raised temperature such as 80°C for a longer reaction time (Ley, S. V. et al, Angew. Chem. Int. Ed. 42 (2003) 5400).
  • Deprotection can be carried out in organic solvent such as DCM or THF with TFA at room temperature to afford stereoisomers Ij.
  • organic solvent such as DCM or THF with TFA at room temperature to afford stereoisomers Ij.
  • the alkylation of Ij with bromide XXIII is carried out by using bases such as NaH, K2CO3 or Cs 2 C0 3 in organic solvents such as THF or DMF at room temperature for several hours.
  • hydrolysis of the methyl ester gives the compounds Ik.
  • the hydrolysis can be carried out in the presence of an aqueous inorganic base such as lithium hydroxide, sodium hydroxide, or potassium hydroxide in a solvent such as methanol, 1,4-dioxane or tetrahydrofuran at room temperature for several hours.
  • Scheme 8 The compounds of formula IL can be prepared according to Scheme 8. The alkylation between IV and ethylene dibromide XXV affords the bromides XXVI.
  • the condensation between IV and ethylene dibromide can be carried out in organic solvents (THF or DMF) by using bases such as NaH, K2CO3 or Cs 2 C0 3 at room temperature for several hours .
  • the substitution reaction between the imidazole XXVII and XXVI can be carried out in organic solvents such as THF or DMF by using bases such as NaH, K 2 C0 3 or Cs 2 C0 3 at room temperature for several hours.
  • hydrolysis of the methyl ester XXVII can afford the compounds IL.
  • the reaction can be carried out in the presence of an aqueous inorganic bases such as lithium hydroxide, sodium hydroxide, or potassium hydroxide in a solvent such as methanol, 1,4- dioxane or tetrahydrofuran at room temperature for several hours.
  • an aqueous inorganic bases such as lithium hydroxide, sodium hydroxide, or potassium hydroxide in a solvent such as methanol, 1,4- dioxane or tetrahydrofuran at room temperature for several hours.
  • the invention also relates to a process for the preparation of a compound of formula (I) comprising one of the following steps: a) the reaction of a compound of formula (A)
  • R 1 , R 2 , R 3 , R 4 and n are defined as in any one of claims 1 to 8; wherein R 5 is hydrogen, halogen, oxo-oxazolidinyl or oxo-imidazolidinyl; wherein R 6 and R 7 are independently selected from hydrogen, alkyl, cycloalkyl, alkylsulfonyl,
  • cycloalkylsulfonyl, aminoalkyl and aminocycloalkyl wherein X is carbon or nitrogen; wherein Y is Br, I, or OTs; wherein Q is Br or I; and wherein R is alkyl.
  • the coupling reagent is for example dicyclohexyl carbodiimide (DCC), benzotriazol-l-yl-oxy-tris-pyrrolidinophosphonium hexafiuorophosphate (PyBop), o-(7- azabenzotriazol-l-yl)-A7,A7,Ar',AT'-tetramethyluronium hexafiuorophosphate (HATU), o- (lH-benzotriazol-l-yl)-A7,A7,AT',Ar'-tetramethyluronium hexafiuorophosphate (HBTU) or l-ethyl-3-(3'-dimethylamino)carbodiimide hydrochloride salt (EDCI).
  • DCC dicyclohexyl carbodiimide
  • PyBop benzotriazol-l-yl-oxy-tris-pyrrolidin
  • Step (a) can be carried out in the presence or absence of hydroxybenzotriazole (HOBt) or N,N- dimethylaminopyridine (DMAP), in the presence of a base such as triethylamine or N,N- diisopropyl ethylamine.
  • the reaction of step (a) can be carried out in a solvent such as dichloromethane or ⁇ , ⁇ -dimethylformamide. The reaction can be carried out at room temperature for several hours.
  • the base can be for example NaH, K2CO3 or CS2CO3.
  • Step (b) can be carried out in an organic solvent such as THF or DMF. This reaction can proceed at room temperature for several hours.
  • the base can be for example NaH, K2CO3 or CS2CO3.
  • Step (c) can be done in an organic solvent such as THF or DMF. The reaction can proceed at room
  • step (d) can be carried out in an organic solvent such as DCM or THF.
  • the reducing agent of step (d) can be for example NaBH 4 or NaHB(OAc)3.
  • the reaction can proceed at room temperature.
  • the base can be for example NaH, K2CO3 or CS2CO3.
  • the solvent can be an organic solvent such as THF or DMF. The reaction can be carried out at room temperature for several hours.
  • the base in step (f), can be an inorganic base such as lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the solvent of step (f) can be for example methanol, 1,4-dioxane or tetrahydrofuran. The reaction can proceed at room temperature for several hours.
  • the base in step (g), can be an inorganic base such as lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the solvent of step (g) can be for example methanol, 1,4-dioxane or tetrahydrofuran. The reaction can proceed at room temperature for several hours.
  • the invention also relates to a compound of formula (I) for use as therapeutically active substance.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) and a therapeutically inert carrier.
  • a compound of formula (I) for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to AMPK regulation is an object of the invention.
  • the invention relates in particular to the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of obesity, hyperglycemia, dyslipidemia, type 1 or type 2 diabetes, in particular type 2 diabetes.
  • Said medicaments e.g. in the form of pharmaceutical preparations, can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions with an effective amount of a compound as defined above.
  • the above-mentioned pharmaceutical composition can be obtained by processing the compounds according to this invention with pharmaceutically inert inorganic or organic carriers.
  • Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical composition can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, fiavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the dosage depends on various factors such as manner of administration, species, age and/or individual state of health.
  • the doses to be administered daily are about 5-400 mg/kg, preferably about 10-100 mg/kg, and can be taken singly or distributed over several administrations.
  • a compound of formula (I) when manufactured according to the above process is also an object of the invention. Furthermore, the invention also relates to a method for the treatment or prophylaxis of diseases that are related to AMPK regulation, which method comprises administering an effective amount of a compound of formula (I).
  • the invention further relates to a method for the treatment or prophylaxis of obesity, hyperglycemia, dyslipidemia, type 1 or type 2 diabetes, in particular type 2 diabetes, which method comprises administering an effective amount of a compound of formula (I).
  • the invention also relates to a compound of formula (I) for the preparation of medicaments useful in the treatment of cancer that are related to AMPK regulation and provides a method for the treatment of cancer that are related to AMPK regulation.
  • Acidic condition A: 0.1% formic acid in H 2 0; B: 0.1% formic acid in acetonitrile;
  • Basic condition A: 0.01% ⁇ 3 ⁇ 2 0 in H 2 0; B: acetonitrile;
  • Oxindole (0.13 g, 1 mmol), 4-chlorobenzaldehyde (0.17 g, 1.2 mmol) were mixed in alcohol; then pyrrolidine (0.17 ml, 2 mmol) was added. The mixture was refluxed for 3 hours. The formed precipitates was collected by filtration and washed with alcohol twice to give the title compound as yellow powder (0.24 g, 92 %).
  • CisHioClNO 255 observed(M+H) + : 256.1.
  • a solution of dimethylsulfoxoniummethylide was prepared as under argon from a 60% NaH mineral oil dispersion (88 mg, 2.2 mmol), trimethylsulfoxoniumiodide (484 mg, 2.2 mmol), and DMSO (10 mL). After 20 min, a solution of (Z)-3-(4-chloro-benzylidene)-l, 3-dihydro-indol-2-one (510 mg, 2 mmol) in THF (5 mL) was added dropwise over 20 min. After stirring for 1 hour at room temperature and another 1 hour at 50°C, the solution was poured into ice-cold water (20 mL) and extracted with ether (3 x 20 mL).
  • 5-Fluoroisatin (64.3 mmol) was suspended in MeOH (300 mL). The suspension was heated to reflux where upon a deep-red solution was obtained. To this hot solution was added tosylhydrazine (64.8 mmol) in one portion. A yellow product started precipitating from the hot mixture. The reaction was allowed to cool to room temperature and the pale tosylhydrazone was filtered off. The product was used for the next step without further purification.
  • the tosylhydrazone (38.1 mmol) was treated with a solution of NaOH (76.1 mmol) in water 375 mL.
  • the reaction mixture was stirred for 15 hours in a water bath at 50°C and then allowed to cool to room temperature.
  • the reaction mixture was neutralized by addition of dry ice whereupon diazo compound was precipitated. (5.94 g, 88%).
  • Example 30 and Example 31 (-)-3-((2-(4-chlorophenyl)-2-isopropyl-2'-oxospiro[(ir ns)-cyclopropane-l,3'- indoline]-l'-yl)methyl)benzoic acid and (+)-3-((2-(4-chlorophenyl)-2-isopropyl-2'- oxospiro [ (trans) -cyclopropane- 1 ,3'-indoline] - 1 '-yl)methyl)benzoic acid
  • the tile compounds were obtained by separation of the stereoisomers of (IS, 2S) and (1R, 2R)-3-((2-(4-chlorophenyl)-2-isopropyl-2'-oxospiro[cyclopropane-l,3'-indoline]-l'- yl)methyl)benzoic acid (Example 32) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • the tile compounds were obtained by separation of the stereoisomers of (IS, 2S) and (1R, 2R)-3-((2-(4-chlorophenyl)-5'-fiuoro-2-isopropyl-2'-oxospiro[cyclopropane-l,3'- indoline] -l'-yl)methyl)benzoic acid (Example 35) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • the tile compounds were obtained by separation of the stereoisomers of (IS, 2S) and (1R, 2R)-3-((2-(4-chlorophenyl)-2-isopropyl-2'-oxospiro[cyclopropane-l,3'-indoline]-l'- yl)methyl)benzoic acid (Example 27) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • the tile compounds were obtained by separation of the stereoisomers of (1R, 2S) and (IS, 2R)-3-((2-(4-chlorophenyl)-2-methyl-2'-oxospiro[cyclopropane-l,3'-indoline]-l'- yl)methyl)benzoic acid (Example 42) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • the tile compounds were obtained by separation of the stereoisomers of (1R, 2R) and (IS, 2S)-3-((2-(4-chlorophenyl)-2-methyl-2'-oxospiro[cyclopropane-l,3'-indoline]-l'- yl)methyl)benzoic acid (Example 45) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • the tile compounds were obtained by separation of the stereoisomers of (1R, 2S) and (IS, 2R)- 3-((2-(4-cyanophenyl)-5'-fiuoro-2-methyl-2'-oxospiro[cyclopropane-l,3'-indoline]- l'-yl)methyl) benzoic acid (Example 48) by chiral preparative HPLC (Chiralpak AD) eluting with a mixture of n-heptane / 5% isopropanol.
  • Example 58 and Example 59
  • Example 65 (IS, 2R) and (1R, 2S)-2-(4-chlorophenyl)-l'-(3-(4-isopropylpiperazine-l-carbonyl) benzyl) spiro [cyclopropane- 1 ,3'-mdolin] -2'-one
  • Example 81 (IS, 2R) and (1R, 2S)-l-(2-(2-(4-chlorophenyl)-2'-oxospiro[cyclopropane-l,3'- indoline] - 1 '-yl) ethyl) - 1 H-imidazole-4-carboxylic acid
  • Example 82 (IS, 2S) and (1R, 2R)-l-(2-(2-(4-chlorophenyl)-2'-oxospiro[cyclopropane-l,3'- indoline] - 1 '-yl) ethyl) - 1 H-imidazole-4-carboxylic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule (I) ainsi qu'un sel pharmaceutiquement acceptable de celui-ci, où R1 à R4 ont la signification donnée dans la revendication 1, qui peut être utilisé en tant que modulateur d'AMPK.
PCT/EP2010/069111 2009-12-11 2010-12-08 Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk WO2011070039A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2012126987/04A RU2012126987A (ru) 2009-12-11 2010-12-08 Спироиндолциклопропаниндолиноны в качестве модуляторов амрк
CA2781839A CA2781839A1 (fr) 2009-12-11 2010-12-08 Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk
JP2012542526A JP2013513569A (ja) 2009-12-11 2010-12-08 Ａｍｐｋモジュレーターとして有用なスピロインドール−シクロプロパンインドリノン
ES10790751.1T ES2464044T3 (es) 2009-12-11 2010-12-08 Espirol indol-ciclopropano indolinonas útiles como moduladores de AMPK
CN2010800558075A CN102656147A (zh) 2009-12-11 2010-12-08 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
EP10790751.1A EP2509946B1 (fr) 2009-12-11 2010-12-08 Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk
BR112012013847A BR112012013847A2 (pt) 2009-12-11 2010-12-08 novos derivados de indolinona ciclopropano
MX2012006180A MX2012006180A (es) 2009-12-11 2010-12-08 Espiro indol-ciclopropano indolinonas utiles como moduladores de proteina cinasa activada por monofosfato de adenosina.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2009/075500 2009-12-11
PCT/CN2009/075500 WO2011069298A1 (fr) 2009-12-11 2009-12-11 Nouveaux dérivés de cyclopropane indolinone

Publications (1)

Publication Number Publication Date
WO2011070039A1 true WO2011070039A1 (fr) 2011-06-16

Family

ID=43447167

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2009/075500 WO2011069298A1 (fr) 2009-12-11 2009-12-11 Nouveaux dérivés de cyclopropane indolinone
PCT/EP2010/069111 WO2011070039A1 (fr) 2009-12-11 2010-12-08 Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/075500 WO2011069298A1 (fr) 2009-12-11 2009-12-11 Nouveaux dérivés de cyclopropane indolinone

Country Status (10)

Country Link
US (2) US8354443B2 (fr)
EP (1) EP2509946B1 (fr)
JP (1) JP2013513569A (fr)
KR (1) KR20120114297A (fr)
BR (1) BR112012013847A2 (fr)
CA (1) CA2781839A1 (fr)
ES (1) ES2464044T3 (fr)
MX (1) MX2012006180A (fr)
RU (1) RU2012126987A (fr)
WO (2) WO2011069298A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014162744A (ja) * 2013-02-25 2014-09-08 Chiba Univ 光学活性スピロシクロプロピルオキシインドール誘導体及びその製造方法
WO2016042194A1 (fr) * 2014-09-19 2016-03-24 Consejo Superior De Investigaciones Científicas (Csic) Dérivés d'indole pour la prévention et/ou le traitement du diabète et de troubles métaboliques associés
US9393232B2 (en) 2013-04-26 2016-07-19 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
WO2019170543A1 (fr) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification et utilisation d'inhibiteurs d'erk5

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756568C (fr) 2009-04-06 2018-02-13 University Health Network Inhibiteurs de kinases et procede de traitement du cancer avec ceux-ci
LT2556071T (lt) * 2010-04-06 2017-01-25 University Health Network Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9364406B2 (en) 2012-10-12 2016-06-14 Regents Of The University Of Minnesota Open chained or fused 1,1′-alkylene-bis-uracil derivatives, useful in skin UV-protection
WO2014062838A2 (fr) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
WO2014202580A1 (fr) * 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Dérivés d'oxindole spiro-substitués ayant une activité sur ampk
KR102195494B1 (ko) 2013-10-18 2020-12-28 유니버시티 헬스 네트워크 췌장암 치료
ES2623082B1 (es) * 2015-12-10 2018-06-20 Consejo Superior De Investigaciones Científicas (Csic) COMPUESTOS ESPIRANICOS DERIVADOS DE OXINDOL-PIRAZOLO [3,4-b] PIRIDINONA Y SUS USOS TERAPÉUTICOS
WO2017127409A1 (fr) 2016-01-20 2017-07-27 Chemocentryx, Inc. Composés de 2-oxindole
ES2646993B1 (es) * 2016-06-17 2018-09-25 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indolin-2-ona y su uso terapéutico
EP3941463A1 (fr) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
CA3178994A1 (fr) 2020-05-19 2021-11-25 Iyassu Sebhat Activateurs d'ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037247A1 (fr) * 2002-10-21 2004-05-06 Irm Llc Oxindoles presentant une forte activite anti-vih
WO2005018568A2 (fr) * 2003-08-20 2005-03-03 Irm Llc Inhibiteurs de la cathepsine s
WO2006023107A1 (fr) * 2004-08-09 2006-03-02 Wyeth Modulateurs de récepteurs de progestérone comprenant des dérivés de pyrrole-oxindole et utilisations de ceux-ci
WO2007008664A1 (fr) * 2005-07-13 2007-01-18 Allergan, Inc. Inhibiteurs de 3-spirocyclopropyl-2-oxindole kinase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
MXPA04001144A (es) * 2001-08-07 2004-07-08 Banyu Pharma Co Ltd Compuestos espiro.
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2006002421A2 (fr) * 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
CA2756568C (fr) * 2009-04-06 2018-02-13 University Health Network Inhibiteurs de kinases et procede de traitement du cancer avec ceux-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037247A1 (fr) * 2002-10-21 2004-05-06 Irm Llc Oxindoles presentant une forte activite anti-vih
WO2005018568A2 (fr) * 2003-08-20 2005-03-03 Irm Llc Inhibiteurs de la cathepsine s
WO2006023107A1 (fr) * 2004-08-09 2006-03-02 Wyeth Modulateurs de récepteurs de progestérone comprenant des dérivés de pyrrole-oxindole et utilisations de ceux-ci
WO2007008664A1 (fr) * 2005-07-13 2007-01-18 Allergan, Inc. Inhibiteurs de 3-spirocyclopropyl-2-oxindole kinase

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
ANSEL, H. ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, pages: 196,1456 - 1457
BASTIN R.J. ET AL., ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, 2000, pages 427 - 435
BRUNMAIR, B ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 25226 - 25232
CARLING, D., TRENDS BIOCHEM SCI, vol. 29, 2004, pages 18 - 24
COOL, B ET AL., CELL METABOLISM, vol. 3, 2006, pages 403 - 416
EL-MIR, MY ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 223 - 228
FOREST M-C ET AL: "A NOVEL CLASS OF CARDIOTONIC AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-SUBSTITUTED 3,6-DIHYDROTHIADIAZIN-2-ONES WITH CYCLIC AMP PHOSPHODIESTERASE INHIBITING AND MYOFIBRILLAR CALCIUM SENSITIZING PROPERTIES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 35, no. 1, 1 January 1992 (1992-01-01), pages 163 - 172, XP002146828, ISSN: 0022-2623, DOI: DOI:10.1021/JM00079A022 *
FRIEDMAN, JM; HALAAS, JL., NATURE, vol. 395, 1998, pages 763 - 770
HARDIE, DG., ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 47, 2007, pages 185 - 210
HARDIE, DG., NATURE REVIEWS, vol. 8, 2007, pages 774 - 785
JIANG T ET AL: "Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 8, 15 April 2006 (2006-04-15), pages 2105 - 2108, XP025106918, ISSN: 0960-894X, [retrieved on 20060415], DOI: DOI:10.1016/J.BMCL.2006.01.073 *
JIANG T ET AL: "Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 8, 15 April 2006 (2006-04-15), pages 2109 - 2112, XP025106919, ISSN: 0960-894X, [retrieved on 20060415], DOI: DOI:10.1016/J.BMCL.2006.01.066 *
KADOWAKI, T ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, 2006, pages 1784 - 1792
KAHN, BB ET AL., CELL METABOLISM, vol. 1, 2005, pages 15 - 25
LEY, S. V. ET AL., ANGEW. CHEM. INT. ED., vol. 42, 2003, pages 5400
LEY, S. V. ET AL., ANGEW.CHERN.INT.ED., vol. 42, 2003, pages 5400
LONG, YC ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, 2006, pages 1776 - 1783
MINOKOSHI, Y ET AL., NATURE, vol. 415, 2002, pages 339 - 343
MOLDVAI ET AL: "Synthesis of Spiro[cyclopropane-1,3'[3H]-2'(1'H)-ones with Antihypoxic Effects", ARCH. PHARM. PHARM. MED. CHEM., vol. 329, no. 12, 1996, pages 541 - 549, XP002617908 *
MONTALBETTI, C. A. G. N. ET AL., TETRAHEDRON, vol. 61, 2005, pages 10827
MORICONI ET AL: "Pyrolysis and Photolysis of 1-Methyl-3-diazooxindole. Base decomposition of Isatin 2-Tosylhydrazone", J. ORG. CHEM., vol. 29, no. 12, December 1964 (1964-12-01), pages 3577 - 3584, XP002617907 *
MUOIO, DM ET AL., DIABETES, vol. 46, 1997, pages 1360 - 1363
OWEN, MR ET AL., THE BIOCHEMICAL JOURNAL, vol. 348, 2000, pages 607 - 614
PANG, T ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 16051 - 16060
SEMPLE, RK ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, 2006, pages 581 - 589
SHAW, RJ ET AL., SCIENCE (NEW YORK), vol. 310, 2005, pages 1642 - 1646
WOODS, A ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 20, 2000, pages 6704 - 6711
YAMAUCHI, T ET AL., NATURE MEDICINE, vol. 7, 2001, pages 941 - 946
YAMAUCHI, T ET AL., NATURE MEDICINE, vol. 8, 2002, pages 1288 - 1295
ZHOU, G ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, 2001, pages 1167 - 1174

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014162744A (ja) * 2013-02-25 2014-09-08 Chiba Univ 光学活性スピロシクロプロピルオキシインドール誘導体及びその製造方法
US9393232B2 (en) 2013-04-26 2016-07-19 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
US9827226B2 (en) 2013-04-26 2017-11-28 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
WO2016042194A1 (fr) * 2014-09-19 2016-03-24 Consejo Superior De Investigaciones Científicas (Csic) Dérivés d'indole pour la prévention et/ou le traitement du diabète et de troubles métaboliques associés
WO2019170543A1 (fr) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification et utilisation d'inhibiteurs d'erk5

Also Published As

Publication number Publication date
KR20120114297A (ko) 2012-10-16
WO2011069298A1 (fr) 2011-06-16
RU2012126987A (ru) 2014-01-20
MX2012006180A (es) 2012-06-19
JP2013513569A (ja) 2013-04-22
US8354443B2 (en) 2013-01-15
US20110144106A1 (en) 2011-06-16
CA2781839A1 (fr) 2011-06-16
BR112012013847A2 (pt) 2016-05-10
US20130102604A1 (en) 2013-04-25
EP2509946B1 (fr) 2014-04-16
ES2464044T3 (es) 2014-05-30
EP2509946A1 (fr) 2012-10-17

Similar Documents

Publication Publication Date Title
EP2509946B1 (fr) Spiro-indole-cyclopropane-indolinones utiles en tant que modulateurs d'ampk
CA2981657A1 (fr) Inhibiteurs de l'indoleamine 2,3-dioxygenase pour le traitement du cancer
KR101569261B1 (ko) 암을 치료하기 위한 hdac 억제제로서 4-아미노-n-하이드록시-벤즈아미드
EA021367B1 (ru) Производное пиридин-3-карбоксамида
ES2920359T3 (es) Amidas de pirrolidinas sustituidas II
EP1716135A1 (fr) Piperidinyl-carbonyl-pyrrolidines et leur utilisation en tant que agonistesde la melanocortine
KR20210114972A (ko) 치환된 피롤리딘 아마이드 iii
AU2019459552A1 (en) Dihydro-pyrrolo-pyrimidine selective JAK2 inhibitor
AU2005314601A1 (en) Indane amides with antiproliferative activity
CN102656147A (zh) 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
US20220106295A1 (en) Substituted pyrrolidine amides iv
WO2020254552A2 (fr) Amides de pyrrolidine substitués v
CN103328446B (zh) 用于治疗癌症的新的4-氨基-n-羟基-苯甲酰胺
CN114573567A (zh) 一种吲唑环联三氮唑类化合物及其制备方法和应用
EP4178954A1 (fr) Pyrrolidine amines substituées et amides en tant que médiateur du récepteur de glucocortoïde
NZ626745A (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055807.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790751

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2010790751

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4317/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2781839

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/006180

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012542526

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20127017856

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012126987

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013847

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013847

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120608